32 results about "Tail suspension test" patented technology

The invention discloses an application of Akkermansia Muciniphila in the preparation of drugs for preventing depression or health products. In vivo pharmacodynamic studies are performed on the effectsof Akkermansia Muciniphila bacteria in depression and anti-depression; results show that the Akkermansia Muciniphila abundance in the intestinal tracts of depression patients is obviously reduced; and animal experiment results show that the Akkermansia Muciniphila abundance in the intestinal tracts of mice is obviously reduced. The Akkermansia Muciniphila bacteria are transplanted to a depressionmouse model, and experiments show that the transplantation of the Akkermansia Muciniphila bacteria can increase the movement distances of the mice and reduce the dead time of tail suspension tests and forced swimming tests, and the depression states of the mice can be significantly alleviated, so that the Akkermansia Muciniphila bacteria show good anti-depression curative effects and has no side-effects yet.

The invention relates to a building method and application of an STCH (stress and chaperone) gene knock-out animal model. The model can function as an animal model for the research of occurrence of depression and / or dementia. The model is prepared by using a gene knock-out technique, animal behavior detections show that a mouse suffers depression-like symptoms (forced swimming test and tail suspension test) and memory dysfunction (water maze test) while it grows older and has depression and dementia-like symptoms, and the model is applicable to screening anti-depression and anti-dementia drugs.

The invention provides new application of sea-buckthorn seed oil extracted from sea-buckthorn seeds, i.e., application of the sea-buckthorn seed oil to preparation of a medicament or a health-care food for preventing and / or treating depression, and application of the sea-buckthorn seed oil serving as a raw material to preparation of the medicament or the health-care food for preventing and / or treating the depression. Test results prove that the immobility time in forced swimming tests of mice and tail suspension tests of the mice can be obviously reduced by the sea-buckthorn seed oil and the sea-buckthorn seed oil has an obvious depression suppression effect. The sea-buckthorn seed oil is a natural anti-depression effective substance which has the advantages of easiness and convenience in preparation, obvious effect, safety, reliability and easiness for industrial production. The sea-buckthorn seed oil can be prepared into formulations such as soft capsules, dropping pills and emulsion for anti-depression medicaments or health care foods.

The invention relates to the technology of pharmacy, and particularly relates to application of oridonin in preparation of anti-depression medicines. The anti-depression medicinal ingredient of the anti-depression medicine provided by the invention is oridonin, and has an efficacy dosage 0.01-30mg oridonin per kilogram of the body weight; and an anti-depression effect can be generated in 60 minutes after the medicine is administrated. The medicine has the advantages of remarkable anti-depression effect, quick response, small dosage, small side effect and the like. In a mammal mouse tail suspension test, the oridonin has a more remarkable anti-depression effect than that of conventional anti-depression medicine imipramine, and is expected to become a novel quick and efficient anti-depression medicine without toxic or side effect.

The invention discloses a sargassum horneri beta-sitosterol compound and an extracting method thereof. The sargassum horneri beta-sitosterol compound has remarkable anti-depression effect, and animal experiments in an embodiment show that beta-sitosterol can remarkably reduce dead time of mice in a mouse forced swimming test and a tail suspension test, takes effect quickly, is small in toxic and side effects (TD50 is greater than 2,000 mg / kg), and can be used for a long time, and pharmacological properties of the sargassum horneri beta-sitosterol compound which has high value and serves as anti-depression drug are shown. The beta-sitosterol compound is abundant in source of raw materials and is low in price, the extracting method is simple, and the beta-sitosterol compound can be prepared into anti-depression drugs in various dosage forms.

The invention discloses an antidepressant drug which takes salvianolic acid B as a raw material and the dose thereof. The invention further discloses a preparation method of the drug. Experiments prove that the drug can significantly reduce the immobility time of the tail suspension test and the forced swimming test of tested mice, thereby inferring that the drug has the effect of anti-experimental depression.

The invention relates to a new use of 20(S)-protopanoxadiol derivatives and 20(S)-protopanaxatriol derivatives, and mainly relates to a use in the preparation of medicines for treating or preventing depressive mental diseases. 20(S)-protopanoxadiol and 20(S)-protopanaxatriol are used as raw materials, and undergo oxidative cyclization to prepare dammara-20S-24(R)-epoxy-3beta,12beta,25-triol, dammara-20S-24(S)-epoxy-3beta,12beta,25-triol, dammara-20S-24(S)-epoxy-3beta,6beta,12beta,25-tetrol or dammara-20S-24(R)-epoxy-3beta,6beta,12beta,25-tetrol. Researches of pharmacological experiments show that dammara-20S-24(R / S)-epoxy-3beta,12beta,25-triol and dammara-20S-24(R / S)-epoxy-3beta,6beta,12beta,25-tetrol can obviously shorten the tail immobility time of mice in mouse tail suspension tests of a classic depression model, and can obviously shorten the swimming immobility time of the mice in mouse forced swimming model tests, so dammara-20S-24(R / S)-epoxy-3beta,12beta,25-triol and dammara-20S-24(R / S)-epoxy-3beta,6beta,12beta,25-tetraol have potential development values in the preparation of medicines for treating or preventing depressive mental diseases.

The invention provides application of atractylenolide in preparation of an antidepressant drug, and relates to the field of medicine. In-vitro activity tests prove that atractylenolide I and atractylenolide III have the better protection activity on corticosterone-damaged PC12 cells, and the mechanism is related to inhibition of neuron apoptosis; in-vivo test results show that atractylenolide I and atractylenolide III can significantly shorten the immobility time of a mouse forced swimming test and a mouse tail suspension test. Experiments prove that atractylenolide I and atractylenolide III have the significant antidepressant effect and can be used for preparing the drug for preventing and treating a depressive disorder.

The invention belongs to the technical field of biopharmaceutics and provides an application of saikosaponin B2 in preparation of an antidepressant drug. A structural formula of saikosaponin B2 is asshown in the specification, and saikosaponin B2 is a unique active ingredient in the antidepressant drug. In-vitro activity tests prove that saikosaponin B2 has better protection activity for PC12 injured by corticosterone, and in-vivo test results show that saikosaponin B2 can significantly shorten immobile time of mice in forced swimming and tail suspension tests. Test results show that saikosaponin B2 has a significant antidepressant effect and can be used for preparing a drug for preventing and treating depression.

The invention relates to a novel chalcone compound Chalcone-1203, and also relates to a preparation method for the compound, a composition using the compound as an active component and application of the compound in preparation of an antidepressant drug. The novel chalcone compound Chalcone-1203 provided by the invention has substantial anti-depression effect. Results of animal testing in the embodiments show that Chalcone-1203 can substantially reduce immobility time of mice in forced swimming test and tail suspension test of the mice, has fast action and small toxic and side effect (TD50>2000 mg / kg), is suitable for long-term usage and shows valuable antidepressant pharmacological properties. The novel chalcone compound uses widely-available and cheap raw materials, is simple to prepare and can be used for preparation of antidepressant drugs of a variety of dosage forms.

The invention discloses an application of aspirin in treatment of cognitive and behavioral disorders after epilepsy. The inventor creates a lithium chloride-pilocarpine induced rat model of chronic epilepsy, detects the spatial learning and memory of the rat through a Morris water maze, detects the behavior depression of the rat through a tail suspension test, and finds that the cognitive function and behavior disorder of the epileptic rat are obviously perfected when being dosed with the aspirin at the chronic epilepsy attack stage.

The invention discloses application of 17-hydroxy-jolkinolide B in preparation of an anti-depression drug. A tail suspension test and a forced swimming test are to place depression model animals in asevere environment, so that the animals cannot escape to generate discontinuously immobile despairing states. The anti-depression drug can relieve the despairing degrees of the depression model animals, so that the immobile states can be reversed, and the depression symptoms can be relieved. Experimental researches find that the 17-hydroxy-jolkinolide B can relieve the despairing degrees of depression model mice, and has an anti-depression effect, and therefore has a prospect of being developed into the anti-depression drug.

The invention discloses application of licorisoflavan A in preparation of drugs for treating depression. Licorisoflavan A is a flavonoid compound separated from a Chinese herb, namely radix glycyrrhizae; the immobilization time of a mouse forced swimming test and tail suspension test of a chronic unpredictable mild stress depression model can be obviously shortened, it is indicated that licorisoflavan A has an excellent anti-depression effect, and by regulating and controlling AMPA receptors, a BDNF-TrkB passage can be adjusted to achieve the anti-depression effect. Licorisoflavan A can be combined with auxiliary agents, used for preparing the drugs for treating depression and applied with other anti-depression drugs.

The invention belongs to the technical field of traditional Chinese medicines and natural medicines, and particularly relates to traditional Chinese medicine composition volatile oil and a preparation method and application thereof. The traditional Chinese medicine composition volatile oil is characterized by comprising the following Chinese herbal medicines by weight: 15-60 parts of mangnolia officinalis and 10-40 parts of perilla leaf. The traditional Chinese medicine composition volatile oil can be prepared into an oral preparation, an inhalant or an externally used ointment by a conventional traditional Chinese medicine preparation method. The beneficial effects of the traditional Chinese medicine composition volatile oil are mainly reflected in that: the traditional Chinese medicine composition volatile oil drug can significantly shorten the forced swimming and tail suspension immobility time of behavioral despair model mice, significantly shorten immobility time in forced swimming test and tail suspension test of chronic stress depression model mice, and significantly increase syrup preference of the chronic stress depression model mice. The result of study shows that the traditional Chinese medicine composition volatile oil has the significant anti experimental depression effect in mice.

The invention relates to an antidepressant effect and application of effective parts of hypericum wightianum. The extraction and separation method of the effective parts of the hypericum wightianum comprises the following steps: degreasing the hypericum wightianum; extracting with a water-alcohol liquid which is prepared from methanol, ethanol, propanol or n-butanol and water with alcohol amount of 0-80%; separating a concentrated solution with resin column chromatography; and carrying out antidepressant pharmacodynamic screening on various separation parts so as to find a separation component with a good antidepressant effect. In the specific embodiment, the component can obviously shorten the immobility time of mice in a tail suspension test and the immobility time of the mice in a forced swimming test, can obviously inhibit mice hypothermia caused by reserpine, and can obviously increase the evasion times of the mice in a learned helplessness test. The effective component of the hypericum wightianum has obvious antidepressant effect, can be used for preparing antidepressant preparations, or used for studying a specific compound in the component and developing antidepressant monomer compound preparations.

The invention provides an asiatic acid derivative compound represented by general formula (I), or a pharmaceutically acceptable salt or ester thereof, or any optical isomer of the asiatic acid derivative compound, or any of tautomer of the asiatic acid derivative compound. The invention also provides a preparation method of the asiatic acid derivative compound, wherein the asiatic acid derivative compound is obtained via structural modification of asiatic acid with microorganisms. The invention also provides applications of any of the compound above in preparation of antidepressant drugs. It is shown by mice forced swimming tests and mice tail suspension tests that the asiatic acid derivative compound possesses relatively high antidepressant activity.

The invention discloses an application of styrax in preparation of anti-depression and anti-anxiety products. The styrax is used for preparing anti-depression and anti-anxiety products which can effectively treat or prevent depression and anxiety disorder. Animal experiments prove the remarkable resisting effects against depression and anxiety. According to a large number of animal experiments, the styrax can increase the time of a mouse staying at the center in an open-field test, reduce the feeding latency of mouse, increase the sweet water preference value and shorten total staying time in a forced swimming test and total staying time in a tail suspension test. In conclusion, the styrax realizes an exact curative effect on depression and anxiety disorder; and meanwhile, as a pure natural extract, the styrax causes few side effects and is safe and convenient to use and is of great significance on preventing and treating depression and anxiety disorder.

The invention discloses application of catalpol in the preparation of an antidepressant medicine. The catalpol can be used as the antidepressant medicine for preventing and treating depression. A mouse forced swimming test (FST), a mouse tail suspension test (TST) and a rat chronic unpredictable mild stress (CUMS) test prove that the catalpol has an obvious antidepressant effect, the antidepressant activity of the catalpol reaches or exceeds that of the anti-depression western medicine fluoxetine commonly used in the clinic, and the catalpol can be used for preparing the medicine for preventing and treating depression.

The invention relates to application of Dendropanax proteus extract in the preparation of anti-depression natural drugs. The Dendropanax proteus extract is made by crushing stems of Dendropanax proteus, soaking the crushed stems with purified water, heating, extracting leachate with 95% ethanol, extracting the extract with 75% ethanol, extracting with petroleum ether, concentrating the liquid extract, and drying. Forced swimming test and tail suspension test of mice show that the Dendropanax proteus extract has significant anti-depression effect and good depression therapeutic effect. Long-term virulence test observation on mice shows that no abnormality occurs, and safety is good; the Dendropanax proteus extract is expectedly developable into novel anti-depression natural drugs.

The invention provides application of coniferyl ferulate to preparing antidepressant drugs, and relates to the field of medicine. The application has the advantages that as proved by in-vitro activity tests, the coniferyl ferulate is excellent in protection activity for PC12 cells injured by corticosterone and glutamic acid; as shown by results of in-vivo tests, the immobility time of mice in forced swimming and tail suspension tests can be obviously shortened by the coniferyl ferulate; as proved by tests, obvious antidepressant effects can be realized by the coniferyl ferulate, and accordingly the coniferyl ferulate can be used for preparing the drugs for preventing and treating depression.

The invention provides new application of sea-buckthorn seed oil extracted from sea-buckthorn seeds, i.e., application of the sea-buckthorn seed oil to preparation of a medicament or a health-care food for preventing and / or treating depression, and application of the sea-buckthorn seed oil serving as a raw material to preparation of the medicament or the health-care food for preventing and / or treating the depression. Test results prove that the immobility time in forced swimming tests of mice and tail suspension tests of the mice can be obviously reduced by the sea-buckthorn seed oil and the sea-buckthorn seed oil has an obvious depression suppression effect. The sea-buckthorn seed oil is a natural anti-depression effective substance which has the advantages of easiness and convenience in preparation, obvious effect, safety, reliability and easiness for industrial production. The sea-buckthorn seed oil can be prepared into formulations such as soft capsules, dropping pills and emulsion for anti-depression medicaments or health care foods.

Cymbopogon schoenanthus is used in folk medicine in North-African for the treatment of rheumatism and to diminish fever. However, whether it possesses anti-stress properties had not previously been established in vivo. Disclosed herein are data demonstrating the effectiveness of C. schoenanthus ethanol extracts on stressors in vitro (heat shock and oxidative stress) and on stressors in vivo (forced swimming test and tail suspension test). Moreover, disclosed are statistically significant anti-stress effects in vivo which occur in a dose-dependent manner. Additionally, the effects of C. schoenanthus ethanol extract exposure is shown to be comparable to a commercially-available antidepressant drug. Accordingly, C. schoenanthus ethanol extracts are useful in new compositions and methods for treating or ameliorating emotional-psychological stress.

The tail suspension test apparatus for detecting a struggling state of an animal by suspending a tail of the animal includes an optical mouse, an opaque piece located within a sensing range of the optical mouse, and a fixing device connected with the opaque piece for fixing the tail of the animal. When the animal is struggling, an action of the opaque piece is induced and detected by the optical mouse.

The invention relates to the technology of pharmacy, and particularly relates to application of oridonin in preparation of anti-depression medicines. The anti-depression medicinal ingredient of the anti-depression medicine provided by the invention is oridonin, and has an efficacy dosage 0.01-30mg oridonin per kilogram of the body weight; and an anti-depression effect can be generated in 60 minutes after the medicine is administrated. The medicine has the advantages of remarkable anti-depression effect, quick response, small dosage, small side effect and the like. In a mammal mouse tail suspension test, the oridonin has a more remarkable anti-depression effect than that of conventional anti-depression medicine imipramine, and is expected to become a novel quick and efficient anti-depression medicine without toxic or side effect.

The invention discloses an application of 'Xinnaoxin' capsule in the preparation of drugs for treating chronic stress depression. Research has shown that the autonomic activities of a model rat reduce, the preference degree on sweet water lowers, the static time in forced-swimming tests and tail suspension tests increases, and these animal depression behaviors are all caused by chronic unpredictable stress. The 'Xinnaoxin' capsule can relieve the deterioration of these depression behaviors.

The invention discloses a microfauna tail fixing device for a tail suspension test, which comprises a box body and further comprises a partition plate for blocking the visual field of an experimentalmouse, the partition plate can be transversely inserted into the box body to divide the interior of the box body into an upper space and a lower space, and a through hole for the tail of the experimental mouse to pass through is formed in the middle of the partition plate; a microfauna tail fixator is arranged in the upper space of the partition plate, the microfauna tail fixator is fixed to the box body through two opposite supports, and the center line of the microfauna tail fixator coincides with the center line of the through hole; the microfauna tail fixator comprises an annular sleeve, aflexible protective layer is arranged on the inner side of the annular sleeve, the annular sleeve comprises a first port and a second port which are detachable, and when the tail of the experimentalmicrofauna passes through the through hole of the partition plate, the first port and the second port are closed so as to fix the tail of the experimental mouse; and a camera device is arranged at thebottom of the box body and is used for collecting video images of the laboratory mouse when the tail part of the laboratory mouse is fixed.

The invention provides the application of coniferyl ferulate in the preparation of antidepressant drugs, and relates to the field of medicine. The present invention proves that coniferyl ferulate has good protective activity on PC12 cells damaged by corticosterone and glutamate through in vitro activity test; in vivo test results show that coniferyl ferulate can significantly shorten the forced swimming and tail suspension tests of mice immobility time. Experiments have proved that coniferyl ferulate has significant antidepressant effect, and can be used to prepare medicines for preventing and treating depression.

The invention provides application of atractylenolide in preparation of an antidepressant drug, and relates to the field of medicine. In-vitro activity tests prove that atractylenolide I and atractylenolide III have the better protection activity on corticosterone-damaged PC12 cells, and the mechanism is related to inhibition of neuron apoptosis; in-vivo test results show that atractylenolide I and atractylenolide III can significantly shorten the immobility time of a mouse forced swimming test and a mouse tail suspension test. Experiments prove that atractylenolide I and atractylenolide III have the significant antidepressant effect and can be used for preparing the drug for preventing and treating a depressive disorder.

The invention discloses application of licorisoflavan A in preparation of drugs for treating depression. Licorisoflavan A is a flavonoid compound separated from a Chinese herb, namely radix glycyrrhizae; the immobilization time of a mouse forced swimming test and tail suspension test of a chronic unpredictable mild stress depression model can be obviously shortened, it is indicated that licorisoflavan A has an excellent anti-depression effect, and by regulating and controlling AMPA receptors, a BDNF-TrkB passage can be adjusted to achieve the anti-depression effect. Licorisoflavan A can be combined with auxiliary agents, used for preparing the drugs for treating depression and applied with other anti-depression drugs.

The invention relates to the field of medicines, and in particular to the application of meptazinol. According to the application of the meptazinol disclosed by the invention, the experiment indicatesthat the meptazinol can achieve the effect of resisting depression through raising the level of Ahi1. Depression resisting model mice are constructed through chronic stress, and then the changes of Ahi1 protein are observed; and the result shows that after 21-day continuous space behavior limit is given to the mice, the depression sample ethology change of the mice is detected through a tail suspension test and a forced swimming test. After the model is successfully constructed, the mice are subjected to intraperitoneal injection according to the dosage of 10mg / kg, physiological saline (NS) is given to the control group, at the same time, space behavior limit is continuously performed each day, the medicine administration time is 12 o'clock at noon and medicine administration is performedfor two weeks continuously; then the depression sample ethology change of the mice is detected by the tail suspension test and the forced swimming test; and then through detection by a Western Blot method, the inventor finds that compared with the Ahi1 protein level of hippocampus of a medicine administration group, the Ahi1 protein level of hippocampus of the depression model mice is notably reduced.